Merry S, Fetherston C A, Kaye S B, Freshney R I, Plumb J A
Br J Cancer. 1986 Jan;53(1):129-35. doi: 10.1038/bjc.1986.18.
We have investigated the mechanism of resistance to adriamycin (ADR) of 3 human glioma cell lines in culture. The cell lines had different inherent sensitivities to ADR. Verapamil increased the ADR sensitivities of the 2 most resistant cell lines (G-UVW and G-CCM) by up to 5-fold. This effect was not seen in a sensitive cell line (G-MCF). Although the accumulation of ADR in the 3 cell lines was not related to inherent sensitivity, energy deprivation or the addition of verapamil produced an increase (up to 46%) in net uptake for both G-UVW and G-CCM, but not for G-MCF. For G-UVW the ADR efflux data were consistent with an energy-dependent ADR efflux mechanism which could be inhibited by verapamil. A similar mechanism was not found for G-CCM. In this cell line verapamil may act by increasing intracellular ADR binding. These data indicate that, while inherent resistance to ADR may be multifactorial, one possible mechanism of resistance in human glioma may involve changes in drug accumulation and/or binding as has been seen in animals models. A potential clinical role for verapamil in overcoming drug resistance in human solid tumours is also indicated.
我们研究了3种培养的人胶质瘤细胞系对阿霉素(ADR)的耐药机制。这些细胞系对ADR具有不同的固有敏感性。维拉帕米使2种耐药性最强的细胞系(G - UVW和G - CCM)对ADR的敏感性提高了5倍。在敏感细胞系(G - MCF)中未观察到这种效应。尽管3种细胞系中ADR的蓄积与固有敏感性无关,但能量剥夺或添加维拉帕米会使G - UVW和G - CCM的净摄取量增加(高达46%),而G - MCF则不然。对于G - UVW,ADR外排数据与一种能量依赖性ADR外排机制一致,该机制可被维拉帕米抑制。在G - CCM中未发现类似机制。在该细胞系中,维拉帕米可能通过增加细胞内ADR结合起作用。这些数据表明,虽然对ADR的固有耐药性可能是多因素的,但人类胶质瘤耐药的一种可能机制可能涉及药物蓄积和/或结合的变化,这在动物模型中也已观察到。这也表明了维拉帕米在克服人类实体瘤耐药性方面的潜在临床作用。